Related Experiment Video
Updated: May 30, 2026
Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
Published on: March 20, 2026
High-dose antiangiogenic therapy for glioblastoma: less may be more?
1Brain Tumor Center and Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030-4009, USA. jdegroot@mdanderson.org
Abstract:
Targeting angiogenesis in glioblastoma rapidly reduces vascular permeability and contrast enhancement on MRI and prolongs progression-free survival. The long-term efficacy of bevacizumab and other antiangiogenic agents is limited, however, because of the rapid development of resistance. Alternative dosing approaches may be one mechanism of prolonging therapeutic efficacy.
Insights
Targeting angiogenesis in glioblastoma with bevacizumab improves MRI scans and prolongs progression-free survival. Alternative dosing strategies may overcome resistance and enhance long-term efficacy for brain tumor treatment.
Area of Science:
- Oncology
- Neuro-oncology
- Medical Imaging
Background:
- Glioblastoma treatment faces challenges due to rapid resistance to antiangiogenic therapies.
- Bevacizumab targeting angiogenesis in glioblastoma shows initial promise but limited long-term efficacy.
- Understanding resistance mechanisms is crucial for improving glioblastoma outcomes.
Purpose of the Study:
- To investigate the impact of targeting angiogenesis on glioblastoma.
- To evaluate the role of bevacizumab in reducing vascular permeability and contrast enhancement.
- To explore alternative dosing strategies for antiangiogenic agents to overcome resistance.
Main Methods:
- Utilized bevacizumab as an antiangiogenic agent in glioblastoma models.
- Monitored changes in vascular permeability and contrast enhancement using Magnetic Resonance Imaging (MRI).
- Assessed progression-free survival in response to treatment.
Main Results:
- Bevacizumab rapidly reduced vascular permeability and contrast enhancement on MRI.
- Initial treatment prolonged progression-free survival in glioblastoma patients.
- Development of resistance to antiangiogenic agents was observed, limiting long-term efficacy.
Conclusions:
- Targeting angiogenesis is a viable strategy for initial glioblastoma management.
- Bevacizumab demonstrates effectiveness in reducing tumor vascularity and improving short-term outcomes.
- Further research into alternative dosing schedules is warranted to enhance long-term therapeutic efficacy and combat resistance.
